The German American Chamber of Commerce awarded Vetter, a globally operating pharmaceutical service provider, the Investment of the Year Award 2026.

The award was officially announced at the German American Business Awards Gala Dinner in New Orleans, LA, on Friday, March 6, 2026, as a part of the 2026 German American Executive Summit. It recognizes Vetter for the significant impact of its $285 million investment in the construction of its new facility in Des Plaines, IL.

The state-of-the-art facility, which will extend Vetter’s presence in the United States, strengthens its position as a leading global partner for aseptic manufacturing in early clinical development. Projected to be operational by the end of 2029, the approximately 160,000 square feet site has the capacity to accommodate future expansion and investments to meet global demands. It will be staffed by up to 200 employees. Vetter celebrated the start of construction with a groundbreaking ceremony in June 2025. The construction is advancing on schedule.

Susanne Lemaine, President of Vetter Development Services USA, said: “We are grateful for this award, which recognizes the growing impact of Vetter’s presence in the U.S. biopharmaceutical market. Our new state‑of‑the‑art facility will further underscore our commitment to supporting customers on their complex journey through clinical development of promising new drugs. By investing in additional capacity, we are responding to the increasing demand for reliable, high‑quality manufacturing services.”

Find pictures and more materials here.

Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the independent pharmaceutical service provider is also present in the Asia-Pacific markets of Japan, China, South Korea and Singapore with sales locations. Around the world renowned pharma and biotech companies benefit from decades of experience, high quality, modern technologies, reliability, and commitment of its 7,300 employees. In close collaboration with its customers, the Vetter team helps enable the supply to patients all over the world with medicines, many of which are vital. The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative approaches, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. Vetter takes responsibility for sustainable practices and operates as a socially and ethically responsible corporate citizen. The CDMO is a member of the UN Global Compact and Science Based Target initiative (SBTi) and received platinum status in the renowned EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership Award and the recognition of Best Managed Company emphasize Vetter’s commitment to sustainable business. Founded in Ravensburg in 1950, the company remains family-owned to this day. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.